4.8 Review

Depression

Journal

LANCET
Volume 392, Issue 10161, Pages 2299-2312

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/S0140-6736(18)31948-2

Keywords

-

Funding

  1. Australian Rotary Health
  2. National Institute of Mental Health
  3. National Health and Medical Research Council
  4. New South Wales Ministry of Health
  5. Ramsay Health
  6. University of Sydney
  7. AstraZeneca
  8. Eli Lilly Co
  9. Organon
  10. Pfizer
  11. Servier
  12. Wyeth

Ask authors/readers for more resources

Major depression is a common illness that severely limits psychosocial functioning and diminishes quality of life. In 2008, WHO ranked major depression as the third cause of burden of disease worldwide and projected that the disease will rank first by 2030.1 In practice, its detection, diagnosis, and management often pose challenges for clinicians because of its various presentations, unpredictable course and prognosis, and variable response to treatment.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available